Long‐term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma‐derived FVIII/VWF product: the long‐term ITI study-Reference-Cited by-同舟云学术

Long‐term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma‐derived FVIII/VWF product: the long‐term ITI study

Published:2016-06-22 Issue:6 Volume:22 Page:859-865
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Jiménez‐Yuste V.¹,Oldenburg J.²,Rangarajan S.³,Peiró‐Jordán R.⁴,Santagostino E.⁵

Affiliation:

1. Haematology Department Hospital Universitario La Paz Universidad Autónoma de Madrid Madrid Spain

2. University Clinic Bonn Institute of Experimental Haematology and Transfusion Medicine Bonn Germany

3. Haemophilia, Haemostasis & Thrombosis Centre Hampshire Hospitals NHS Foundation Trust Basingstoke UK

4. Scientific and Medical Affairs Department Grifols Sant Cugat del Vallès Barcelona Spain

5. Centro Emofilia e Trombosi “Angelo Bianchi Bonomi” Fondazione IRCCS Ca' Granda Milano ltalia

Funder

Baxter International

Bayer

Biogen Idec

Roche

CSL Behring

Novo Nordisk

Pfizer

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.12986

Reference24 articles.

1. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

2. Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: a systematic review

3. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom

4. Immune Tolerance for the Treatment of Factor VIII Inhibitors - Twenty Years' ‘Bonn Protocol’

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab for All Pediatric Patients with Severe Hemophilia A;Hämostaseologie;2022-04

2. Immune Tolerance Induction in Patients with Hemophilia A;Advances in Hemophilia Treatment;2022

3. Emerging drugs for hemophilia A: insights into phase II and III clinical trials;Expert Opinion on Emerging Drugs;2021-10-02

4. Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients;Thrombosis Research;2021-09

5. Low‐dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors;Research and Practice in Thrombosis and Haemostasis;2021-07